Compare FSFG & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSFG | XBIT |
|---|---|---|
| Founded | 2008 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 221.5M | 73.2M |
| IPO Year | 2008 | 2015 |
| Metric | FSFG | XBIT |
|---|---|---|
| Price | $32.44 | $2.45 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $31.50 | N/A |
| AVG Volume (30 Days) | 18.0K | ★ 57.7K |
| Earning Date | 01-27-2026 | 11-12-2025 |
| Dividend Yield | ★ 1.97% | N/A |
| EPS Growth | ★ 67.68 | N/A |
| EPS | ★ 3.32 | N/A |
| Revenue | ★ $84,223,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.81 | ★ N/A |
| Revenue Growth | ★ 23.59 | N/A |
| 52 Week Low | $21.63 | $2.09 |
| 52 Week High | $33.35 | $4.67 |
| Indicator | FSFG | XBIT |
|---|---|---|
| Relative Strength Index (RSI) | 54.48 | 49.81 |
| Support Level | $32.06 | $2.40 |
| Resistance Level | $32.85 | $2.55 |
| Average True Range (ATR) | 0.46 | 0.10 |
| MACD | -0.11 | 0.00 |
| Stochastic Oscillator | 46.84 | 22.00 |
First Savings Financial Group Inc provides various banking services to individuals and business customers in southern Indiana. The bank accepts deposits from the general public & uses those funds, along with other borrowings, mainly to originate a residential mortgage, commercial mortgage, construction, commercial business, & consumer loans, and to a lesser extent, to invest in mortgage-backed securities and other debt securities. The company conducts lending and deposit activities mainly with individuals and small businesses in its market area. The bank operates in two segments: core banking, which accounts for the majority of revenue, and SBA lending.
XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-inflammatory therapeutic antibodies as a treatment for cancer. Geographically, all of its operations are in the United States.